Efavirenz: all 156 studies that test it

Page 1 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Efavirenz for the Treatment of Creutzfeldt-Jakob DiseaseRecruitingNCT07482085Phase 3
• The T Cell Activator of Cell Killing ("TACK") IT ON" STUDYRecruitingNCT06823596Not applicable
• Reverse Triple Negative Immune Resistant Breast CancerRecruitingNCT05076682Phase 2
• Efavirenz (EFV) IntensificationCompletedNCT07193875Phase 4Results posted
• A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy ParticipantsCompletedNCT04459598Phase 1Results posted
• Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 PatientsCompletedNCT01989910Phase 4Results posted
• Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With EfavirenzTerminatedNCT01980342Phase 4Results posted
• Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ARTCompletedNCT01903031Phase 2Results posted
• Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.CompletedNCT01878890Phase 1Results posted
• Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or EfavirenzCompletedNCT01695954Phase 1Results posted
• Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child TransmissionCompletedNCT01618305Phase 4Results posted
• Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative StressCompletedNCT01585038Phase 4Results posted
• Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral SuppressionCompletedNCT01387022Not applicableResults posted
• Treatment Options for Protease Inhibitor-exposed ChildrenCompletedNCT01146873Phase 3Results posted
• Cryptococcal Optimal ART Timing TrialCompletedNCT01075152Phase 4Results posted
• Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.CompletedNCT01011413Phase 3Results posted
• HIV Protease Inhibitors for the Prevention of Malaria in Ugandan ChildrenCompletedNCT00978068Phase 3Results posted
• Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00964171Phase 2Results posted
• Efavirenz in Treating Patients With Metastatic Prostate CancerCompletedNCT00964002Phase 2Results posted
• A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc TherapyCompletedNCT00870363Phase 4Results posted
• Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2CompletedNCT00810303Phase 1Results posted
• Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV DiseaseTerminatedNCT00775606Phase 4Results posted
• Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 InfectionCompletedNCT00734344Not applicableResults posted
• A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRTCompletedNCT00727597Phase 3Results posted
• Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir TherapyCompletedNCT00661960Not applicableResults posted
• KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive SubjectsCompletedNCT00549198Phase 4Results posted
• Mechanisms of Lipodystrophy in HIV-Infected PateintsCompletedNCT00457665Phase 4Results posted
• HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIVCompletedNCT00442962Phase 4Results posted
• Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected ChildrenCompletedNCT00364793Phase 1/2Results posted
• Antiretroviral Therapy for Advanced HIV Disease in South AfricaCompletedNCT00342355Phase 4Results posted
• ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial RegimensCompletedNCT00335322Phase 4Results posted
• Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic ImpairmentCompletedNCT00162097Phase 1Results posted
• Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive AdultsCompletedNCT00118898Phase 3Results posted
• Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at BirthCompletedNCT00102960Phase 3Results posted
• Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited SettingsCompletedNCT00084136Phase 4Results posted
• Preventing Sexual Transmission of HIV With Anti-HIV DrugsCompletedNCT00074581Phase 3Results posted
• Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV DrugsCompletedNCT00016718Phase 1/2Results posted
• A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)CompletedNCT06797674Phase 1
• A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)CompletedNCT06698016Phase 1
• TGRX-326 Pharmacokinetic Drug InteractionCompletedNCT06294561Phase 1
• A Trial of DDI Between SHR1459 and Efavirenz With Healthy SubjectsCompletedNCT05560360Phase 1
• Drug-drug Interaction Study of Ganaplacide and Lumefantrine With EfavirenzCompletedNCT05330273Phase 1
• Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A InducerStatus unknownNCT04680091Phase 1
• Efavirenz 400mg in Treatment-naïve Chinese HIV-infected PatientsCompletedNCT04596488Not applicable
• Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected PatientsStatus unknownNCT04513379Phase 3
• Efficacy of Efavirenz 400mg vs. 600mg Combined With Lamivudine and Tenofovir in Treatment Naive HIV InfectionStatus unknownNCT04463784Not applicable
• A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.CompletedNCT04390334Phase 1
• Bioavailability Mechanistic Study of Hot-Melt Extruded Amorphous Solid DispersionsCompletedNCT03886766Not applicable
• Efavirenz for Patients With Alzheimer's DiseaseCompletedNCT03706885Phase 1
• Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and TenofovirCompletedNCT03309566Phase 4
• Dosing of Tenofovir and Efavirenz in Antiretroviral TherapyCompletedNCT02945163Phase 4
• Optimization of Antiretroviral TherapyCompletedNCT02935075Phase 4
• Pharmacokinetics of Efavirenz in the Presence of Rifampicin and IsoniazidStatus unknownNCT02832778Phase 1
• Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected WomenCompletedNCT02722421Phase 2
• ART Drug Dosage Adjustment in HIV-infected PopulationCompletedNCT02632474Phase 4
• SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected WomenCompletedNCT02499874Phase 1
• Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai PatientsStatus unknownNCT02421289Phase 1
• Efavirenz to Dolutegravir Switch in Patients With CNS ToxicityStatus unknownNCT02285374Phase 4
• Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisCompletedNCT02273765Phase 3
• Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult VolunteersCompletedNCT02226991Phase 1
• Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy SubjectsCompletedNCT02164812Phase 1
• LAAM-HAART PET ImagingCompletedNCT01935830Early Phase 1
• Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV CoinfectionCompletedNCT01900015Phase 4
• BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infectionStatus unknownNCT01641016Phase 2/3
• A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy VolunteersCompletedNCT01588002Phase 1
• The Mochudi Prevention Project ART ProtocolTerminatedNCT01583439Not applicable
• Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or RifampinCompletedNCT01571414Phase 1
• The Neurocognitive Sub-study of Encore1CompletedNCT01516060Phase 3
• The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1CompletedNCT01451333Phase 3
• A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)CompletedNCT01445223Phase 4
• The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)CompletedNCT01271894Phase 3
• A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female VolunteersCompletedNCT01268839Phase 1
• TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and RaltegravirCompletedNCT01241773Phase 1
• PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA TrialCompletedNCT01192035Phase 4
• Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of CytochromesCompletedNCT01187862Phase 1
• GSK1349572 Drug Interaction Study With EfavirenzCompletedNCT01098526Phase 1
• Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral TherapyStatus unknownNCT01049685Phase 4
• Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection StatusCompletedNCT01040091Phase 1
• Appropriate Timing of HAART in Co-infected HIV/TB PatientsTerminatedNCT01014481Phase 4
• Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy VolunteersCompletedNCT00992069Phase 1
• CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment RegimesCompletedNCT00966160Phase 3
• Disulfiram Interactions With HIV Medications: Clinical ImplicationsCompletedNCT00878306Phase 1
• Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and EfavirenzCompletedNCT00792584Not applicable
• Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125CompletedNCT00792324Phase 3
• Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid MetabolismStatus unknownNCT00759070Phase 4
• TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.CompletedNCT00744809Phase 1
• Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase InhibitorsCompletedNCT00730223Phase 1
• Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug CombinationsCompletedNCT00697892Phase 1
• Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual DosageCompletedNCT00556634Phase 4
• Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIVCompletedNCT00545558Phase 1
• Pediatric Expanded Access Program-Oral Solution (0831-908)CompletedNCT00543530Phase 3
• Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mgTerminatedNCT00533390Phase 4
• Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/MclCompletedNCT00532168Phase 4
• HIV Antiretroviral Drugs and MetabolismStatus unknownNCT00525239Not applicable
• A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIVTerminatedNCT00523458Phase 4
• Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving RifampinCompletedNCT00483054Phase 3
• A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected SubjectsCompletedNCT00476424Phase 2
• Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With TuberculosisStatus unknownNCT00474435Phase 2
• Drug Interaction - Oral ContraceptiveCompletedNCT00399685Phase 1
• Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.TerminatedNCT00386659Phase 4

← Efavirenz overview